Postmenopausal women may benefit from treatment and prevention of osteoporosis with the help of selective estrogen receptor modulator (SERM) raloxifene HCl (hydrochloride). It resembles estrogen’s impacts on bone density, which might aid in the preservation of bone strength and lower some fracture risk.
Reducing low-density lipoprotein (LDL) cholesterol levels, raloxifene may have a beneficial influence on lipid profiles.
In postmenopausal women with osteoporosis or those at high risk for breast cancer, raloxifene could also lower their risk of invasive breast cancer. Over a 47-month period, the STAR (Study of Tamoxifen and Raloxifene) study demonstrated that raloxifene was as effective as tamoxifen at decreasing the chance. Postmenopausal women above 35 who have higher risk of developing breast cancer. Invasive breast cancer in these women. While both tamoxifen and raloxifene raise the chance of blood clot formation, the raloxifene group experienced 28% less deep-vein thromboses and 20% less pulmonary embolisms than the tamoxifen group. Raloxifene, however, lowered the risk of invasive breast cancer by roughly 38 percent after an average of 81 months; tamoxifen reduced the risk by about 50 percent.

Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Raloxifene.” MedlinePlus, U.S. National Library of Medicine, medlineplus.gov/druginfo/meds/a698007.html.
2. “Raloxifene.” PubChem, National Center for Biotechnology Information, pubchem.ncbi.nlm.nih.gov/compound/Raloxifene.
3. National Center for Biotechnology Information (NCBI). Raloxifene. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK544233/– LinkOpens in New Tab
4. “Raloxifene and Breast Cancer Risk Reduction.” National Cancer Institute, https://www.cancer.gov/types/breast/research/star-trial-results-qa